KRAS mutant lung cancer: progress thus far on an elusive therapeutic target

The KRAS mutation remains the most common driver mutation in patients with non-small cell lung cancer (NSCLC) and confers a poor prognosis. Thus far, efforts to target this mutation over the last two decades have been unsuccessful. Over the past 5 years, many efforts to develop drugs that target the...

Descripción completa

Detalles Bibliográficos
Autores principales: Bhattacharya, Saveri, Socinski, Mark A., Burns, Timothy F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2015
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4678136/
https://www.ncbi.nlm.nih.gov/pubmed/26668062
http://dx.doi.org/10.1186/s40169-015-0075-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4678136/
https://www.ncbi.nlm.nih.gov/pubmed/26668062
http://dx.doi.org/10.1186/s40169-015-0075-0

Ejemplares similares